RT Journal
A1 Kuehn BM
T1 PNeumonia vaccine
JF JAMA
JO JAMA
YR 2012
FD February 22
VO 307
IS 8
SP 773
OP 773
DO 10.1001/jama.2012.176
UL http://dx.doi.org/10.1001/jama.2012.176
AB 
The vaccine, named Prevnar 13, was already approved for use in infants and children up to age 5 years to prevent otitis media and other illnesses caused by Streptococcus pneumoniae in this age group. But pneumonia caused by this organism is a major public health problem for older individuals, leading to 300 000 hospitalizations each year among persons 50 years and older. Public health efforts such as Healthy People 2020 have prioritized interventions to prevent such infections.